BetterScholar BetterScholar

Christopher N. Johnson

Journal of Medicinal Chemistry, ACS Central Science, Proceedings of the National Academy of Sciences of the United States of America, Bioscience Reports
9
Role
Title
Level Year L/R
🐬 Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Honorine Lebraud, D. J. Wright, Christopher N. Johnson, T. Heightman 		8 2016
8
🐬
🐜 Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist
23 auth. L. Burdelya, C. Brackett, B. Kojouharov, I. Gitlin, K. Leonova, A. Gleiberman, Semra Aygun‐Sunar, J. Veith, Christopher N. Johnson, Gary J Haderski, ... P. Stanhope-Baker, S. Allamaneni, J. Skitzki, Mingyue Zeng, E. Martsen, A. Medvedev, D. Scheblyakov, Nataliya M Artemicheva, D. Logunov, A. Gintsburg, B. Naroditsky, S. Makarov, A. Gudkov 		6 2013
6
🐜
🐜 Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP.
19 auth. G. Chessari, I. Buck, James E H Day, P. Day, A. Iqbal, Christopher N. Johnson, E. J. Lewis, V. Martins, Darcey Miller, M. Reader, ... D. Rees, S. Rich, E. Tamanini, M. Vitorino, G. Ward, Pamela A. Williams, Glyn Williams, N. Wilsher, A. Woolford 		6 2015
6
🐜
🐜 Investigation of the scope of a [3+2] cycloaddition approach to isoxazole boronic esters
7 auth. Jane E. Moore, M. W. Davies, K. M. Goodenough, R. Wybrow, M. York, Christopher N. Johnson, ... J. Harrity 		5 2005
5
🐜
🐜 MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells
17 auth. Lijs Beke, Cenk Kığ, J. Linders, Shannah Boens, An Boeckx, E. V. van Heerde, M. Paradé, A. de Bondt, Ilse van den Wyngaert, T. Bashir, ... Souichi Ogata, L. Meerpoel, A. Van Eynde, Christopher N. Johnson, M. Beullens, D. Brehmer, M. Bollen 		5 2015
5
🐜
🐜 Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP).
19 auth. E. Tamanini, I. Buck, G. Chessari, E. Chiarparin, James E H Day, M. Frederickson, C. Griffiths-Jones, K. Hearn, T. Heightman, A. Iqbal, ... Christopher N. Johnson, E. J. Lewis, V. Martins, T. Peakman, M. Reader, S. Rich, G. Ward, Pamela A. Williams, N. Wilsher 		5 2017
5
🐜
🐜 Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.
21 auth. G. Macdonald, C. Branch, M. Hadley, Christopher N. Johnson, D. Nash, Alexander B Smith, G. Stemp, K. Thewlis, A. Vong, N. Austin, ... P. Jeffrey, Kim Y Winborn, I. Boyfield, J. Hagan, D. Middlemiss, C. Reavill, G. Riley, J. Watson, M. Wood, S. G. Parker, C. Ashby 		5 2003
5
🐜
🐬 Fragment-to-Lead Medicinal Chemistry Publications in 2020
I. D. de Esch, D. Erlanson, W. Jahnke, Christopher N. Johnson, Louise Walsh 		5 2021
5
🐬
🐬 Fragment-to-Lead Medicinal Chemistry Publications in 2018.
D. Erlanson, I. D. de Esch, W. Jahnke, Christopher N. Johnson, Paul N. Mortenson 		5 2020
5
🐬